Lists of diseases

Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Tuesday, October 25, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diamond, Lists of diseases, Master of Science, Drug design, Diamond Light Source, University of Nottingham, GSK, Therapy, Disease, Hope, Science, Amphisbaena, Nobel Prize, University, Max Planck Institute of Biochemistry, Drug development, Research, Joint Planning and Development Office, Villigen, Astex, Institute, Partnership, Olaparib, Artificial intelligence, Cancer, Gene, Max Planck Society, Probability, University College London, Drug discovery, Atlas, Doctor of Philosophy, Industry, Charles River Laboratories, Gesellschaft mit beschränkter Haftung, Cancer Research UK, Genetics, Genome, Head, GW Pharmaceuticals, Pharmaceutical industry, IND, Chemistry, Dodi Protero, Adrasteia

Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.

Key Points: 
  • Im thrilled to be working with James and Proteros were poised to deliver some revolutionary new medicines.
  • He has led or been involved with the delivery of seven drug candidates across a range of target classes.
  • In Jamess most recent position he ran the medicinal chemistry function at Amphista Therapeutics.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new targets for treating intractable genetic diseases.

Global Physiotherapy Equipment Market Report (2022 to 2027) - Increasing Demand for Home Healthcare Services Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Medical Devices, Health, Electrotherapy, Laser, Arthritis, Hospital, Incidence, Population, Cerebrovascular disease, Human musculoskeletal system, Cryotherapy, Sports injury, 3D ultrasound, CAGR, Hydrotherapy, Pediatrics, Acupuncture, Community, Therapy, Sport, Disability, Palliative care, Safety, Stroke, Neurology, Alzheimer's disease, Conditional sentence, Lists of diseases, USD, Patient, Healthcare, Veterinary medicine, Gynaecology

The global physiotherapy equipment market is projected to reach USD 24.5 billion by 2027 from USD 18.4 billion in 2022, at a CAGR of 6.0% during the forecast period.

Key Points: 
  • The global physiotherapy equipment market is projected to reach USD 24.5 billion by 2027 from USD 18.4 billion in 2022, at a CAGR of 6.0% during the forecast period.
  • Based on product, the physiotherapy equipment market is segmented into equipment and accessories.
  • The equipment is further segmented into electrotherapy equipment, ultrasound equipment, exercise therapy equipment, heat therapy equipment, cryotherapy equipment, combination therapy equipment, continuous passive motion therapy equipment, shockwave therapy equipment, laser therapy equipment, magnetic pressure therapy equipment, traction therapy, and other physiotherapy equipment (hydrotherapy and vacuum therapy).
  • Market growth in the Asia Pacific is attributed to the growing number of healthcare facilities and increasing healthcare expenditures.

Global OTC Topical Drugs Market Report 2022: Increasing Number of Skin Diseases and the Prevalence of Musculoskeletal Pain Driving Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Health, Pharmaceutical, Cream, Online, Skin, Prevalence, Growth, Country, Population, Drug class, Analgesic, Distribution, Pfizer, Antibiotic, Piramal, Novartis, Global, APAC, Research, Astringent, Crowding, Pain management, Investment, Skin condition, Sanofi, MEA, Mometasone, Industry, Personal care, Teva Pharmaceuticals, Market share, Lists of diseases, OTC, Lists of countries and territories, Hospital, Life expectancy, Formulation, COVID-19, USD, Consumer, Eye, Pharmaceutical industry, Medical device, Health insurance, Healthcare, Petroleum jelly, Antipruritic, Bayer, Lotion

According to a research report published in August 2022, the Global OTC Topical drugs market was valued at USD 44.6 billion in the year 2021.

Key Points: 
  • According to a research report published in August 2022, the Global OTC Topical drugs market was valued at USD 44.6 billion in the year 2021.
  • The global OTC Topical Drugs Market is driven by an increasing number of skin diseases and the prevalence of musculoskeletal pain across the globe.
  • The report analyses the OTC Topical Drugs Market By Indication (Skin Disease management, Pain Management, Eye and Ear care, Others)
    The report analyses the OTC Topical Drugs Market by End User (Personal Care, Hospitals and clinics and others).
  • The Global OTC Topical Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).

G42 Healthcare Strengthens Clinical Genomics Offering with Saphetor’s VarSome Bioinformatics Platform, Strengthens UAE’s Position as a Global Leader in Healthcare Innovation

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Technology, Other Health, Health, Biometrics, Oncology, Other Technology, Medical Devices, Apps, Applications, Software, Internet, API, Health care, Life, Population, Diagnosis, Vaccine, Lists of diseases, Genomics, Volunteering, Hospital, Research, Publication, Partnership, Cancer, Technology, DNA sequencing, Disorder, NGS, Health, AI, Founder, CEO, IROS, International Grape Genome Program, Omics, Next Generation, Classification, COVID-19, Solution, Medical device, Medical imaging, Pharmaceutical industry, G42

The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies, with the shortest turnaround time.

Key Points: 
  • The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies, with the shortest turnaround time.
  • This collaboration also enables clinical genomics, at scale, as a service, using G42 Healthcares 3 genomic sequencing platforms offering both long and short read capabilities.
  • The collaboration will fortify G42 Healthcares clinical genomics solutions by leveraging the VarSome suite of bioinformatics tools to deliver valuable data insights and improved outcomes.
  • VarSome Premium and VarSome Clinical are professional editions of VarSome with powerful functionality and further sophisticated data-mining and analysis tools.

Peptide Therapeutics Global Market Report 2022: Featuring Amgen, Pfizer, Bristol-Myers Squibb, Sanofi & AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Health, Pharmaceutical, Benchmark, American Hospital Association, Therapy, Prevalence, Efficiency, Growth, Dermatology, Asia-Pacific, Infection, Acromegaly, Patient, Drug development, Hospital, Degenerative disease, AHA, Research, Coronavirus, Chronic condition, Artificial intelligence, Cancer, Immune system, Route of administration, Administration, Conditional sentence, Patent, Lists of diseases, Smokeless tobacco, Create, Peptide, COVID-19, Fine chemical, Marketing

The "Peptide Therapeutics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peptide Therapeutics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the peptide therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • An increase in the prevalence of chronic diseases is expected to propel the growth of the peptide therapeutics market.
  • Therefore, the increase in the prevalence of chronic diseases is expected to drive the peptide therapeutics market during the forecast period.

Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Retrieved on: 
Monday, October 24, 2022
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Vivo, Therapy, SEC, Conference, IND, Hope, NASDAQ, Lists of diseases, Patient, Depression, Investigational New Drug, Security (finance), Coronavirus, Data, Addiction, Technology, Mouse, Food, Company, MD, Nature, Intention, Anxiety, Phrase, HTR, Forward-looking statement, FDA, COVID-19, FOCUS, Pharmaceutical industry

Enveric Biosciences Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the nomination of EB-373 as the lead development candidate to emerge from its EVM201 program.

Key Points: 
  • Enveric Biosciences Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the nomination of EB-373 as the lead development candidate to emerge from its EVM201 program.
  • EB-373 is under development for the treatment of anxiety disorders.
  • Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders.
  • Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Scenic Biotech Appoints Jens Würthner as Chief Medical Officer

Retrieved on: 
Monday, October 24, 2022
Health, Technology, Other Technology, Software, Pharmaceutical, Biotechnology, National Institutes of Health, AstraZeneca, Therapy, Pharmacology, Lists of diseases, Laboratory, Patient, Biotechnology, Molecular Biology of the Cell, Publication, Technology, University, Oscar, University of Hamburg, National Cancer Institute, Doctor of Philosophy, MD, Health, Novartis, GlaxoSmithKline, National, CEO, ADC, King's College, CD47, Gene, List of life sciences, Loncastuximab tesirine, Pharmaceutical industry

Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced today the appointment of Jens Wrthner, MD, PhD, as Chief Medical Officer.

Key Points: 
  • Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced today the appointment of Jens Wrthner, MD, PhD, as Chief Medical Officer.
  • Dr. Wrthner brings Scenic Biotech 20 years of clinical development expertise.
  • I am excited to work alongside Oscar and everyone at Scenic Biotech as we advance a broad portfolio of disease-modifying therapeutics for the benefit of patients, added Dr. Jens Wrthner, Chief Medical Officer of Scenic Biotech.
  • By understanding the genomes power to correct toward health, Scenic Biotech will bring novel therapeutics to patients in need.

Pair Team Appoints New Chief Product Officer and Head of Care Operations to Executive Leadership Team

Retrieved on: 
Monday, October 24, 2022
Mental Health, Technology, Other Technology, Health Technology, Health Insurance, Software, Networks, Other Health, General Health, Health, Transport, Population, Anderson, Patient, Multimedia, RN, Technology, Homelessness, Automation, Health, CPO, Community, Head, Lists of diseases, Management, Medicine

Pair Team , the tech-enabled team that connects underserved communities to high-quality care while addressing patients' barriers to care, announced today that Todd Anderson and Connie Kim have joined the companys executive leadership team.

Key Points: 
  • Pair Team , the tech-enabled team that connects underserved communities to high-quality care while addressing patients' barriers to care, announced today that Todd Anderson and Connie Kim have joined the companys executive leadership team.
  • Anderson will serve as Chief Product Officer and Kim will serve as Head of Care Operations.
  • View the full release here: https://www.businesswire.com/news/home/20221024005082/en/
    Pair Team has appointed Todd Anderson as Chief Product Officer to lead and facilitate the creation and continuous improvement of the companys technology platform.
  • Never before has reimagining the operations of primary care been so necessary to infrastructurally improve outcomes while reducing costs, said Pair Team co-founder and CEO Neil Batlivala.

More Than 350 Latin American Doctors Take Part in the Region's Second Ferrer Summit

Retrieved on: 
Monday, October 24, 2022
Health, Hospitals, Surgery, Neurology, Pharmaceutical, Cardiology, The New England Journal of Medicine, Aspirin, CNIC, Cardiology, Social change, Tree, Translation, Patient, Hospital, Farmer, Gastroenterology, Ramipril, Workforce, Multimedia, Mortality, Lists of diseases, George C. Marshall European Center for Security Studies, Home Away from Homer, Atorvastatin, Learning, Neurology, CEO, Awareness, Ferrer, Wind, Dominican Republic, Summit, NEJM, Environment, Travel, USD, Spanish National Center for Biotechnology, CO2, Medical device, Medicine, Renewable energy, Pharmaceutical industry

With the participation of more than 350 specialist doctors from Latin American countries such as Panama, Guatemala, El Salvador, Nicaragua, Honduras, the Dominican Republic, Colombia, Bolivia, Chile, Paraguay, Peru, Mexico, Costa Rica, and Argentina, the second LatAm Ferrer Summit was held in Panama.

Key Points: 
  • With the participation of more than 350 specialist doctors from Latin American countries such as Panama, Guatemala, El Salvador, Nicaragua, Honduras, the Dominican Republic, Colombia, Bolivia, Chile, Paraguay, Peru, Mexico, Costa Rica, and Argentina, the second LatAm Ferrer Summit was held in Panama.
  • Over two days, the specialists had the opportunity to attend presentations on the latest scientific advances in these four therapeutic areas.
  • Under this Treedom project that Ferrer is partnering, so far more than 3 million trees have been planted in Africa, South America and Asia.
  • We empower and support these professionals in their learning and wellbeing so that they feel proud to work in our company.

Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022

Retrieved on: 
Wednesday, October 26, 2022
Bipolar I disorder, Opioid, Alkermes, Webcast, Research, Investor, ALKS, Schizophrenia, Lists of diseases, Nasdaq, Cancer

DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m.

Key Points: 
  • DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m.
  • ET (12:00 p.m. GMT) on Wednesday, Nov. 2, 2022 to discuss the company's third quarter financial results.
  • The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com .
  • Alkermes plcis a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology.